RecruitingNot ApplicableNCT04513028

Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma


Sponsor

Kelly McMasters

Enrollment

30 participants

Start Date

Nov 3, 2020

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to determine how beta-glucan affects the immune system in subjects with melanoma.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is exploring whether adding beta-glucan (a natural supplement found in oats and mushrooms) can improve how well the immunotherapy drug pembrolizumab works in people with advanced melanoma (stage III or IV skin cancer). **You may be eligible if...** - You have been diagnosed with stage III or IV melanoma - You are currently starting or continuing pembrolizumab as a treatment and show no active signs of disease - You are 18 years or older - You are able to swallow pills - You are in good enough health to participate **You may NOT be eligible if...** - You have had an allergic reaction to beta-glucan before - You are currently taking ongoing immune-suppressing medications Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTBeta-Glucan

500mg (1 capsule) by mouth twice a day for 21 days.


Locations(1)

University of Louisville

Louisville, Kentucky, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04513028


Related Trials